medigraphic.com
ISSN 2448-8747 (Impreso)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2016, Número 1

<< Anterior

Sal Jal 2016; 3 (1)


Experiencia con el uso de inhibidor de la proteína quinasa C (tamoxifeno) en la manía: Reporte de caso

Aldana-López JA, Medina-Dávalos R

Idioma: Español
Referencias bibliográficas: 30
Paginas: 54-59
Archivo PDF: 308.21 Kb.


RESUMEN

Los tratamientos convencionales para los episodios de manía en el Trastorno Bipolar (TB), en ocasiones traen consigo problemas de tolerabilidad, seguridad, o una respuesta inadecuada a los mismos, haciendo necesaria la investigación y desarrollo de nuevos agentes terapéuticos basados en aproximaciones fisiopatológicas del TB. La vía de señalización intracelular de la proteína quinasa C (PKC) se ha visto implicada en el TB, y el tamoxifeno, como su inhibidor directo, es actualmente uno de los fármacos innovadores en manía. Reportamos la experiencia del tratamiento con tamoxifeno en un paciente con TB en manía aguda, discutiéndose su mecanismo de acción, y comparando uso clínico, respuesta terapéutica, y perfil de efectos secundarios con los de la literatura.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Calabrese JR, Hirschfi el RM, Reed M. “Impact of bipolar disorder on U.S. community sample”. J Clin Psychiatry 2003; 64: 425–32.

  2. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders. Fift h Edition. DSM-5

  3. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press 2007, London.

  4. Gitlin M. “Treatment-resistant bipolar disorder”. Mol Psychiatry 2006; 11: 227–40.

  5. Evins AE, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G. “A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania”. Bipolar Disord 2006; 8: 75–80.

  6. Nierenberg AA. “A critical appraisal of treatments for bipolar disorder”. Prim Care Companion J Clin Psychiatry 2010; 12: 23–9.

  7. Manji HK, Lenox RH. “Protein Kinase C Signaling in the Brain: Molecular Transduction of Mood Stabilization in the Treatment of Manic-Depressive Illness”. Biol Psychiatry 1999; 46: 1328– 1351.

  8. Machado-Vieira R, et al. “New therapeutic targets for mood disorders”. Sci World J 2010; 10: 713–726.

  9. Wang HY, Friedman E. “Enhanced protein kinase C activity and translocation in bipolar aff ective disorder brains”. Biol Psychiatry 1996; 40: 568–575.

  10. Szabo ST, et al. “Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of Mania”. Neuropharmacology 2009; 56: 47–55.

  11. Moretti M, et al. “Tamoxifen eff ects on respiratory chain complexes and creatine kinase activities in an animal model of mania”. Pharmacol Biochem Behav 2011; 98: 304–310.

  12. Abrial E, et al. “Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog Neuropsychopharmacol” Biol Psychiatry 2013; 43: 40–48.

  13. Valvassori SS, et al. “Eff ects of tamoxifen on tricarboxylic acid cycle enzymes in the brain of rats submitted to an animal model of mania induced by amphetamine”. Psychiatry Res 2014; 215: 483–487.

  14. Chen G, Masana MI, Manji HK. “Lithium regulates PKCmediated intracellular cross-talk and gene expression in the CNS in vivo”. Bipolar Disord 2000; 2: 217–236.

  15. Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H. “Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha”. J Mol Neurosci 2004; 24: 237-245.

  16. Hahn CG, Umapathy, Wang HY, Koneru R, Levinson DF, Friedman E. “Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients”. J Psychiatr Res 2005; 39: 355–363.

  17. Zarate Jr CA, et al. “Effi cacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study”. Bipolar Disord 2007: 9: 561–570.

  18. Baum AE., et al. “A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder”. Mol Psychiatry. 2008; 13(2): 197-207.

  19. Bebchuk JM, Arfk en CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. “A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania”. Arch Gen Psychiatry 2000; 57: 95–97.

  20. DiazGranados N, Zarate CA. “A Review of the Preclinical and Clinical Evidence for Protein Kinase C as a Target for Drug Development for Bipolar Disorder”. Curr Psychiatry Rep 2008; 10: 510–519.

  21. Sabioni P, Baretta IP, Ninomiya EM, Gustafson L, Rodrigues ALS, Andreatini R. “Th e antimanic-like eff ect of tamoxifen: Behavioural comparison with other PKC-inhibiting and antiestrogenic drugs”. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1927–1931.

  22. Goldstein JA. “Danazol and the rapid-cycling patient”. J Clin Psychiatry 1986; 47(3):153–4.

  23. Kulkarni J, et al. “A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania”. Psychoneuroendocrinology 2014; 43: 52-61.

  24. Pereira M, Martynhak BJ, Baretta IP, Correia D, Siba IP, Andreatini R. “Antimanic-like eff ect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene”. Neurosci Lett 2011; 500: 95– 98

  25. Yatham LN, et al. “Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update” 2013. Bipolar Disord 2013: 15: 1–44.

  26. Kulkarni J, et al. (2006) “A pilot study of hormone modulation as a new treatment for mania in women with bipolar aff ective disorder”. Psychoneuroendocrinology 31: 543–547.

  27. Yildiz A, Guleryuz S, Ankerst DP, et al. “Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen”. Arch Gen Psychiatry 2008; 65: 255–263.

  28. Amrollahi Z, et al. (2011) “Double-blind, randomized, placebocontrolled 6-week study on the effi cacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania”. J Aff ect Disord 129: 327–331.

  29. Lopez M, Lelliott CJ, Tovar S, et al. “Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA”. Diabetes 2006; 55: 1327–1336.

  30. Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH. “Clinical recognition and management of depression in nodenegative breast cancer patients treated with tamoxifen”. Breast Cancer Res Treat 1993; 27: 277–281.




2020     |     www.medigraphic.com